In This Article:
Cyclopharm (ASX:CYC) First Half 2024 Results
Key Financial Results
-
Revenue: AU$13.2m (down 19% from 1H 2023).
-
Net loss: AU$7.51m (loss widened by 159% from 1H 2023).
-
AU$0.078 loss per share (further deteriorated from AU$0.032 loss in 1H 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Cyclopharm Earnings Insights
Looking ahead, revenue is forecast to grow 43% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Medical Equipment industry in Australia.
Performance of the Australian Medical Equipment industry.
The company's shares are down 3.9% from a week ago.
Risk Analysis
Be aware that Cyclopharm is showing 1 warning sign in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.